miR-634 activates the mitochondrial apoptosis pathway and enhances chemotherapy-induced cytotoxicity

Cancer Research

Volumn 75, Issue 18, 2015, Pages 3890-3901

  Fujiwara, Naoto ^a   Inoue, Jun ^a   Kawano, Tatsuyuki ^a   Tanimoto, Kousuke ^a   Kozaki, Ken Ichi ^b   Inazawa, Johji ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b OKAYAMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLUOROURACIL; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 2; MICRORNA; MICRORNA 634; MITOCHONDRIAL TRANSCRIPTION FACTOR A; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS; ALKYLATING AGENT; MIRN-634 MICRORNA, HUMAN; RNA; SMALL INTERFERING RNA; TUMOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APAF1 INTERACTING PROTEIN GENE; APOPTOSIS; ARTICLE; AUTOPHAGY; BACULOVIRAL IAP REPEAT CONTAINING 5 GENE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CONTROLLED STUDY; DRUG CYTOTOXICITY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; GENE; GENE EXPRESSION; GENE IDENTIFICATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LYSOSOMAL ASSOCIATED MEMBRANE PROTEIN 2 GENE; MITOCHONDRIAL GENE; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRION; MOUSE; NONHUMAN; OPTIC ATROPHY 1 GENE; PRIORITY JOURNAL; X LINKED INHIBITOR OF APOPTOSIS E3 UBIQUITIN PROTEIN LIGASE GENE; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; CARCINOMA, SQUAMOUS CELL; DRUG RESISTANCE; DRUG SCREENING; ESOPHAGEAL NEOPLASMS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE THERAPY; GENETIC TRANSFECTION; GENETICS; MULTIMODALITY CANCER THERAPY; NUDE MOUSE; ORGANELLE BIOGENESIS; OXIDATIVE STRESS; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; APOPTOSIS; AUTOPHAGY; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CISPLATIN; COMBINED MODALITY THERAPY; DRUG RESISTANCE, NEOPLASM; ESOPHAGEAL NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC THERAPY; HUMANS; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICE; MICE, INBRED BALB C; MICE, NUDE; MICRORNAS; MITOCHONDRIA; NEOPLASM PROTEINS; ORGANELLE BIOGENESIS; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; RNA, NEOPLASM; RNA, SMALL INTERFERING; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84942875868     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-15-0257     Document Type: Article

References (46)

1. Ambros V. The functions of animal microRNAs. Nature 2004;431:350-5.
2. Zhao Y, Srivastava D. A developmental view of microRNA function. Trends Biochem Sci 2007;32:189-97.
3. Zhang BH, Pan XP, Cobb GP, Anderson TA. microRNAs as oncogenes and tumor suppressors. Dev Biol 2007;302:1-12.
4. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005;120:15-20.
5. Kozaki K, Inazawa J. Tumor-suppressive microRNA silenced by tumorspecific DNA hypermethylation in cancer cells. Cancer Sci 2012;103:837-45
6. Tsuruta T, Kozaki K, Uesugi A, Furuta M, Hirasawa A, Imoto I, et al. miR-152 is a tumor suppressormicroRNA that is silenced by DNA hypermethylation in endometrial cancer. Cancer Res 2011;71:6450-62.
7. Uesugi A, Kozaki K, Tsuruta T, Furuta M, Morita K, Imoto I, et al. The tumor suppressive microRNA miR-218 targets the mTOR component Rictor and inhibits AKT phosphorylation in oral cancer. Cancer Res 2011;71:5765-78.
8. Endo H, Muramatsu T, Furuta M, Uzawa N, Pimkhaokham A, Amagasa T, et al. Potential of tumor-suppressive miR-596 targeting LGALS3BP as a therapeutic agent in oral cancer. Carcinogenesis 2013;34:560-9.
9. Harazono Y, Muramatsu T, Endo H, Uzawa N, Kawano T, Harada K, et al. miR-655 is an EMT-suppressive microRNA targeting ZEB1 and TGFBR2. PLoS One 2013;8:e62757.
10. Yamamoto S, Inoue J, Kawano T, Kozaki K, Omura K, Inazawa J. The impact of miRNA-based molecular diagnostics and treatment of NRF2-stabilized tumors. Mol Cancer Res 2014;12:58-68.
11. Igney FH, Krammer PH. Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer 2002;2:277-88.
12. Gorrini C, Harris IS, Mak TW. Modulation of oxidative stress as an anticancer strategy. Nat Rev Drug Discov 2013;12:931-47.
13. Sui X, Chen R, Wang Z, Huang Z, Kong N, Zhang M, et al. Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment. Cell Death Dis 2013;4:e838.
14. Shimada Y, Imamura M, Wagata T, Yamaguchi N, Tobe T. Characterization of twenty one newly established esophageal cancer cell lines. Cancer 1992;69:277-84.
15. Tanaka H, Shibagaki I, Shimada Y, Wagata T, Imamura M, Ishizaki K. Characterization of p53 gene mutations in esophageal squamous cell carcinoma cell lines: increased frequency and different spectrum of mutations from primary tumors. Int J Cancer 1996;65:372-6.
16. Tanaka H, Shimada Y, Imamura M, Shibagaki I, Ishizaki K. Multiple types of aberrations in the p16 (INK4a) and the p15 (INK4b) genes in 30 esophageal squamous-cell-carcinoma cell lines. Int J Cancer 1997;70:437-42.
17. Olichon A, Baricault L, Gas N, Guillou E, Valette A, Belenguer P, et al. Loss of OPA1 perturbates the mitochondrial inner membrane structure and integrity, leading to cytochrome c release and apoptosis. J Biol Chem 2003;278:7743-6.
18. Kanki T, Ohgaki K, Gaspari M, Gustafsson CM, Fukuoh A, Sasaki N, et al. Architectural role of mitochondrial transcription factor A in maintenance of human mitochondrial DNA. Mol Cell Biol 2004;24:9823-34.
19. Saleem M, Qadir MI, Perveen N, Ahmad B, Saleem U, Irshad T, et al. Inhibitors of apoptotic proteins: new targets for anticancer therapy. Chem Biol Drug Des 2013;82:243-51.
20. Cheung CH, Huang CC, Tsai FY, Lee JY, Cheng SM, Chang YC, et al. Survivin - biology and potential as a therapeutic target in oncology. Onco Targets Ther 2013;6:1453-62.
21. Cho DH, Hong YM, Lee HJ, Woo HN, Pyo JO, Mak TW, et al. Induced inhibition of ischemic/hypoxic injury by APIP, a novel Apaf-1-interacting protein. J Biol Chem 2004;279:39942-50.
22. Green DR, Levine B. To be or not to be? How selective autophagy and cell death govern cell fate. Cell 2014;157:65-75.
23. Kabeya Y, Mizushima N, Ueno T, Yamamoto A, Kirisako T, Noda T, et al. LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J 2000;19:5720-8.
24. Klionsky DJ, Abdalla FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, Adeli K, et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 2012;8:445-544.
25. Hassan M, Watari H, Abu Almaaty A, Ohba Y, Sakuragi N. Apoptosis and molecular targeting therapy in cancer. Biomed Res Int 2014;2014:150845.
26. Czabotar PE, Lessene G, Strasser A, Adams JM. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol 2014;15:49-63.
27. Baba Y, Watanabe M, Yoshida N, Baba H. Neoadjuvant treatment for esophageal squamous cell carcinoma. World J Gastrointest Oncol 2014;6:121-8.
28. Takashima N, Ishiguro H, Kuwabara Y, Kimura M, Mitui A, Mori Y, et al. Gene expression profiling of the response of esophageal carcinoma cells to cisplatin. Dis Esophagus 2008;21:230-5.
29. Kushnareva YE, Gerencser AA, Bossy B, Ju WK, White AD, Waggoner J, et al. Loss of OPA1 disturbs cellular calcium homeostasis and sensitizes for excitotoxicity. Cell Death Differ 2013;20:353-65.
30. Zhao X, Tian C, Puszyk WM, Ogunwobi OO, Cao M, Wang T, et al. OPA1 downregulation is involved in sorafenib-induced apoptosis in hepatocellular carcinoma. Lab Invest 2013;93:8-19.
31. Ueta E, Sasabe E, Yang Z, Osaki T, Yamamoto T. Enhancement of apoptotic damage of squamous cell carcinoma cells by inhibition of the mitochondrial DNA repairing system. Cancer Sci 2008;99:2230-7.
32. Wang J, Silva JP, Gustafsson CM, Rustin P, Larsson NG. Increased in vivo apoptosis in cells lacking mitochondrial DNA gene expression. Proc Natl Acad Sci U S A 2001;98:4038-43.
33. González-Polo RA, Boya P, Pauleau AL, Jalil A, Larochette N, Souquére S, et al. The apoptosis/autophagy paradox: autophagic vacuolization before apoptotic death. J Cell Sci 2005;118:3091-102.
34. Peng X, Cao P, He D, Han S, Zhou J, Tan G, et al. MiR-634 sensitizes nasopharyngeal carcinoma cells to paclitaxel and inhibits cell growth both in vitro and in vivo. Int J Clin Exp Pathol 2014;7:6784-91.
35. Östling P, Leivonen SK, Aakula A, Kohonen P, Mäkelä R, Hagman Z, et al. Systematic analysis of microRNAs targeting the androgen receptor in prostate cancer cells. Cancer Res 2011;71:1956-67.
36. Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer 2013;13:714-26.
37. Liu S, Zhang P, Chen Z, Liu M, Li X, Tang H. MicroRNA-7 downregulates XIAP expression to suppress cell growth and promote apoptosis in cervical cancer cells. FEBS Lett 2013;587:2247-53.
38. Xie Y, Tobin LA, Camps J, Wangsa D, Yang J, Rao M, et al. MicroRNA-24 regulates XIAP to reduce the apoptosis threshold in cancer cells. Oncogene 2013;32:2442-51.
39. Cao W, Yang W, Fan R, Li H, Jiang J, Geng M, et al. miR-34a regulates cisplatin-induce gastric cancer cell death by modulating PI3K/AKT/survivin pathway. Tumour Biol 2014;35:1287-95.
40. Ma Q, Wang X, Li Z, Li B, Ma F, Peng L, et al. microRNA-16 represses colorectal cancer cell growth in vitro by regulating the p53/survivin signaling pathway. Oncol Rep 2013;29:1652-8.
41. Comincini S, Allavena G, Palumbo S, Morini M, Durando F, Angeletti F, et al. microRNA-17 regulates the expression of ATG7 and modulates the autophagy process, improving the sensitivity to temozolomide and lowdose ionizing radiation treatments in human glioblastoma cells. Cancer Biol Ther 2013;14:574-86.
42. Xu Y, An Y, Wang Y, Zhang C, Zhang H, Huang C, et al. miR-101 inhibits autophagy and enhances cisplatin-induced apoptosis in hepatocellular carcinoma cells. Oncol Rep 2013;29:2019-24.
43. Pan B, Chen Y, Song H, Xu Y, Wang R, Chen L. Mir-24-3p downregulation contributes to VP16-DDP resistance in small-cell lung cancer by targeting ATG4A. Oncotarget 2015;6:317-31.
44. Hayes J, Peruzzi PP, Lawler S. MicroRNAs in cancer: biomarkers, functions and therapy. Trends Mol Med 2014;20:460-9.
45. Rothschild SI. microRNA therapies in cancer. Mol Cell Ther 2014;2:7.
46. Bleiberg H, Conroy T, Paillot B, Lacave AJ, Blijham G, Jacob JH, et al. Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer. Eur J Cancer 1997;33:1216-20.